Additionally, while intranasal GAL (1–15) induces a prodepressive effect, prior research and our data support its efficacy as an adjunct to SSRIs for modulating depression-related behaviors, suggesting a dual therapeutic strategy that is tailored to the specific disorder. The gene discussed is GAL; the disease is depressive disorder.